Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.1% in the afternoon session after the ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment & Supplies industry. Ideally ...

According to Benzinga Pro, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.29%, which means the company has less short interest than most of its peers. Did ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories (NYSE:ABT) received an upgrade from Jefferies, which raised its rating to Buy from Hold, stating that the ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The week is set to be active with various corporate actions, including several companies going ex-trade for dividends, bonus ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...